

Charles Catton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8257457/publications.pdf>

Version: 2024-02-01

50
papers

1,035
citations

516561

16
h-index

434063

31
g-index

51
all docs

51
docs citations

51
times ranked

1640
citing authors

#	ARTICLE	IF	CITATIONS
1	ASO Visual Abstract: The Effect of Preoperative Treatment on the Performance of Predictive Nomograms in Primary Retroperitoneal Sarcoma (RPS). <i>Annals of Surgical Oncology</i> , 2022, 29, 2315.	0.7	0
2	Effect of Preoperative Treatment on the Performance of Predictive Nomograms in Primary Retroperitoneal Sarcoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 2304.	0.7	3
3	Survival outcomes of metastatic renal cell carcinoma (mRCC) with sarcomatoid differentiation (SD): A single-institutional experience and literature meta-analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 332-332.	0.8	0
4	Dosimetric comparison of MR-guided adaptive IMRT versus 3DOF-VMAT for prostate stereotactic radiotherapy. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2022, 21, 64-70.	0.6	0
5	Prostate cancer survivor capacity to engage in survivorship self-management: a comparison of perceptions between oncology specialists, primary care, and survivors. <i>Supportive Care in Cancer</i> , 2022, , 1.	1.0	0
6	Circulating tumor DNA (ctDNA) detection of molecular residual disease (MRD) as a potential biomarker in localized soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2022, 40, 11547-11547.	0.8	1
7	Prostate or bone? Comparing the efficacy of image guidance surrogates for pelvis and prostate radiotherapy using accumulated delivered dose. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2021, 52, 14-21.	0.2	1
8	Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 835.e1-835.e7.	0.8	3
9	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. <i>European Urology</i> , 2021, 80, 374-382.	0.9	49
10	Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	3
11	Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2020, 396, 1413-1421.	6.3	226
12	[¹⁸ F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. <i>BMJ Open</i> , 2020, 10, e035959.	0.8	8
13	Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2020, 14, 404-410.	0.3	3
14	A biochemical definition of cure after brachytherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2020, 149, 64-69.	0.3	48
15	Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life. <i>Radiotherapy and Oncology</i> , 2020, 149, 240-245.	0.3	10
16	Impact of Immobilization on Interfractional Errors for Upper Extremity Soft Tissue Sarcoma Radiation Therapy. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2019, 50, 308-316.	0.2	1
17	The evolution of fractionated prostate cancer radiotherapy. <i>Lancet, The</i> , 2019, 394, 361-362.	6.3	8
18	Long-term oncological outcomes of patients with paratesticular sarcoma. <i>BJU International</i> , 2019, 124, 801-810.	1.3	13

#	ARTICLE	IF	CITATIONS
19	Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors. <i>EClinicalMedicine</i> , 2019, 17, 100215.	3.2	42
20	Patterns of Practice Survey: Radiotherapy for Soft Tissue Sarcoma of the Extremities. <i>Cureus</i> , 2019, 11, e6153.	0.2	4
21	Evidence-based region of interest matching guidelines for sarcoma volumetric image-guided radiation therapy. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2018, 5, 3-8.	0.6	2
22	Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres. <i>European Journal of Cancer</i> , 2018, 105, 19-27.	1.3	56
23	Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: Expert opinion and review of the evidence. <i>Canadian Urological Association Journal</i> , 2018, 12, E415-20.	0.3	2
24	Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 123, 459-465.	0.3	18
25	Survival outcomes for cutaneous angiosarcoma of the scalp versus face. <i>Head and Neck</i> , 2017, 39, 1205-1211.	0.9	42
26	Evaluation of high dose volumetric CT to reduce inter-observer delineation variability and PTV margins for prostate cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 125, 118-123.	0.3	16
27	The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer. <i>Radiation Oncology</i> , 2017, 12, 50.	1.2	7
28	Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 93-98.	0.3	23
29	External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer. <i>Canadian Urological Association Journal</i> , 2017, 11, 94.	0.3	0
30	Long-Term Quality of Life of Retroperitoneal Sarcoma Patients Treated with Pre-Operative Radiotherapy and Surgery. <i>Cureus</i> , 2017, 9, e1764.	0.2	10
31	Planned versus "delivered" bladder dose reconstructed using solid and hollow organ models during prostate cancer IMRT. <i>Radiotherapy and Oncology</i> , 2016, 119, 417-422.	0.3	8
32	Lessons learned using an MRI-only workflow during high-dose-rate brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2016, 15, 147-155.	0.2	28
33	Brachytherapy Improves Biochemical Failure-Free Survival in Low- and Intermediate-Risk Prostate Cancer Compared With Conventionally Fractionated External Beam Radiation Therapy: A Propensity Score Matched Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 505-516.	0.4	57
34	Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: preliminary outcomes. <i>Neuro-Oncology</i> , 2015, 17, 889-894.	0.6	93
35	Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes. <i>Practical Radiation Oncology</i> , 2015, 5, e473-e482.	1.1	24
36	Delineating the inner bladder surface using uniform contractions from the outer surface under variable bladder filling conditions. <i>British Journal of Radiology</i> , 2015, 88, 20140818.	1.0	2

#	ARTICLE	IF	CITATIONS
37	Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas. <i>Oncotarget</i> , 2015, 6, 39127-39139.	0.8	14
38	Development of ProCaRS Clinical Nomograms for Biochemical Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated External Beam Radiation Therapy for Localized Prostate Cancer. <i>Cureus</i> , 2015, 7, e276.	0.2	8
39	Long-term complications in men who have early or late radiotherapy after radical prostatectomy.. <i>Canadian Urological Association Journal</i> , 2014, 8, 253.	0.3	31
40	In Regard to Freedland et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 237-240.	0.4	4
41	Spatial and volumetric changes of retroperitoneal sarcomas during pre-operative radiotherapy. <i>Radiotherapy and Oncology</i> , 2014, 112, 308-313.	0.3	19
42	The promise and challenge of minimally invasive therapy. <i>Canadian Urological Association Journal</i> , 2013, 3, 142.	0.3	0
43	The Effects of External Beam Radiotherapy on the Normal Urinary Bladder—A Histopathological Review. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2011, 42, 189-197.	0.2	3
44	PROSTATE RADIOTHERAPY AFTER RADICAL PROSTATECTOMY: SOONER OR LATER?. <i>BJU International</i> , 2010, 106, 946-948.	1.3	1
45	The role of radiation therapy in prostate cancer after radical prostatectomy: when and why?. <i>Current Opinion in Supportive and Palliative Care</i> , 2010, 4, 135-140.	0.5	3
46	Salvage radiotherapy following radical prostatectomy. <i>World Journal of Urology</i> , 2003, 21, 243-252.	1.2	8
47	Recurrent prostate cancer following external beam radiotherapy. <i>Urologic Clinics of North America</i> , 2003, 30, 751-763.	0.8	27
48	Clinical and biochemical outcome of conventional dose radiotherapy for localized prostate cancer. <i>Canadian Journal of Urology</i> , 2002, 9, 1444-52; discussion 1453.	0.0	13
49	A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma. <i>Cancer</i> , 2001, 92, 303-310.	2.0	73
50	Contemporary radiotherapy for soft tissue sarcoma. , 1999, 17, 33-46.		20